-
1Academic Journal
Συγγραφείς: G. L. Ignatova, V. N. Antonov, E. V. Blinova, M. S. Belsner, Г. Л. Игнатова, В. Н. Антонов, Е. В. Блинова, М. С. Бельснер
Πηγή: PULMONOLOGIYA; Том 34, № 1 (2024); 115-120 ; Пульмонология; Том 34, № 1 (2024); 115-120 ; 2541-9617 ; 0869-0189
Θεματικοί όροι: антифибротическая терапия, progressive fibrotic phenotype, antifibrotic therapy, прогрессирующий фибротический фенотип
Περιγραφή αρχείου: application/pdf
Relation: https://journal.pulmonology.ru/pulm/article/view/4469/3606; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4469/2489; Wong A.W., Ryerson C.J., Guler S.A. Progression of fibrosing interstitial lung disease. Respir. Res. 2020; 21 (1): 32. DOI:10.1186/s12931-020-1296-3.; Kataoka K., Oda K., Takizawa H. et al. Cohort study to evaluate prognostic factors in idiopathic pulmonary fibrosis patients introduced to oxygen therapy. Sci. Rep. 2023; 13 (1): 13664. DOI:10.1038/s41598-023-40508-8.; Zamora-Legoff J.A., Krause M.L., Crowson C.S. et al. Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2017; 69 (3): 542–549. DOI:10.1002/art.39971.; Guler S.A., Winstone T.A., Murphy D. et al. Does systemic sclerosis-associated interstitial lung disease burn out? Specific phenotypes of disease progression. Ann. Am. Thorac. Soc. 2018; 15 (12): 1427–1433. DOI:10.1513/AnnalsATS.201806-362OC.; Reiseter S., Gunnarsson R., Mogens Aaløkken T. et al. Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study. Rheumatology (Oxford). 2018; 57 (2): 255–262. DOI:10.1093/rheumatology/kex077.; Cottin V., Wollin L., Fischer A. et al. Fibrosing interstitial lung diseases: knowns and unknowns. Eur. Respir. Rev. 2019; 28 (151): 180100. DOI:10.1183/16000617.0100-2018.; Goh N.S., Hoyles R.K., Denton C.P. et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol. 2017; 69 (8): 1670–1678. DOI:10.1002/art.40130.; Solomon J.J., Chung J.H., Cosgrove G.P. et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur. Respir. J. 2016; 47 (2): 588–596. DOI:10.1183/13993003.00357-2015.; Maher T.M., Corte T.J., Fischer A. et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir. Med. 2020; 8 (2): 147–157. DOI:10.1016/S2213-2600(19)30341-8.; Collard H.R., Ryerson C.J., Corte T.J. et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am. J. Respir. Crit. Care Med. 2016; 194 (3): 265–275. DOI:10.1164/rccm.201604-0801CI.; Karayama M., Aoshima Y., Suzuki T. et al. A predictive model for acute exacerbation of idiopathic interstitial pneumonias. Eur. Respir. J. 2023; 61 (5): 2201634. DOI:10.1183/13993003.01634-2022.; Khor Y.H., Ng Y., Barnes H. et al. Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review. Eur. Respir. Rev. 2020; 29 (157): 190158. DOI:10.1183/16000617.0158-2019.; Mooney J., Reddy S.R., Chang E. et al. Antifibrotic therapies reduce mortality and hospitalization among medicare beneficiaries with idiopathic pulmonary fibrosis. J. Manag. Care Spec. Pharm. 2021; 27 (12): 1724–1733. DOI:10.18553/jmcp.2021.27.12.1724.; Zinellu A., Fois A.G., Pirina P. et al. A systematic review and meta-analysis of clinical, respiratory, and biochemical risk factors for acute exacerbation of idiopathic pulmonary fibrosis. Arch. Med. Res. 2023; 54 (4): 319–331. DOI:10.1016/j.arcmed.2023.04.002.; Macnee W., Walden I.M. Lung research funding in the UK: the British Lung Foundation perspective. Thorax. 1998, 53 (4): 239–240. DOI:10.1136/thx.53.4.239; Jeganathan N., Smith R.A., Sathananthan M. Mortality trends of idiopathic pulmonary fibrosis in the United States from 2004 through 2017. Chest. 2021; 159 (1): 228–238. DOI:10.1016/j.chest.2020.08.016.; Petnak T., Lertjitbanjong P., Thongprayoon C., Moua T. Impact of antifibrotic therapy on mortality and acute exacerbation in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Chest. 2021; 160 (5): 1751–1763. DOI:10.1016/j.chest.2021.06.049.; de Andrade J.A., Neely M.L., Hellkamp A.S. et al. Effect of antifibrotic therapy on survival in patients with idiopathic pulmonary fibrosis. Clin. Ther. 2023; 45 (4): 306–315. DOI:10.1016/j.clinthera.2023.03.003.; Platenburg M.G.J.P., van Moorsel C.H.M., Wiertz I.A. et al. Improved survival of IPF patients treated with antifibrotic drugs compared with untreated patients. Lung. 2023; 201 (4): 335–343. DOI:10.1007/s00408-023-00628-4.; Vancheri C. Common pathways in idiopathic pulmonary fibrosis and cancer. Eur. Respir. Rev. 2013; 22 (129): 265–272. DOI:10.1183/09059180.00003613.; Torrisi S.E., Pavone M., Vancheri A., Vancheri C. When to start and when to stop antifibrotic therapies. Eur. Respir. Rev. 2017; 26 (145): 170053. DOI:10.1183/16000617.0053-2017.; Авдеев С.Н., Айсанов З.Р., Белевский А.С. и др. Идиопатический легочный фиброз: федеральные клинические рекомендации по диагностике и лечению. Пульмонология. 2022; 32 (3): 473–495. DOI:10.18093/0869-0189-2022-32-3-473-495.; https://journal.pulmonology.ru/pulm/article/view/4469
-
2Academic Journal
Συγγραφείς: Avdeev, Sergey N., Chikina, Svetlana Yu., Tyurin, Igor’ E., Belevskiy, Andrey S., Terpigorev, Stanislav A., Anan’yeva, Lidiya P., Vizel’, Aleksandr A., Boldina, Marina V., Demko, Irina V., Leshchenko, Igor’ V., Trofimenko, Irina N., Kinyaykin, Mikhail F., Stepanyan, Igor’ E., Zaytseva, Anna S., Petrov, Dmitriy V., Авдеев, С. Н., Чикина, С. Ю., Тюрин, И. Е., Белевский, А. С., Терпигорев, С. А., Ананьева, Л. П., Визель, А. А., Болдина, М. В., Демко, И. В., Лещенко, И. В., Трофименко, И. Н., Киняйкин, М. Ф., Степанян, И. Э., Зайцева, А. С., Петров, Д. В.
Θεματικοί όροι: INTERSTITIAL LUNG DISEASES, PROGRESSIVE FIBROSING PHENOTYPE, NINTEDANIB, ANTIFIBROTIC, ALGORITHM, ИНТЕРСТИЦИАЛЬНЫЕ ЗАБОЛЕВАНИЯ ЛЕГКИХ, ФИБРОЗИРУЮЩИЕ ИНТЕРСТИЦИАЛЬНЫЕ ЗАБОЛЕВАНИЯ ЛЕГКИХ, ПРОГРЕССИРУЮЩИЙ ФЕНОТИП, АНТИФИБРОТИЧЕСКАЯ ТЕРАПИЯ, АЛГОРИТМ, НИНТЕДАНИБ
Περιγραφή αρχείου: application/pdf
Relation: Пульмонология; http://elib.usma.ru/handle/usma/4827
Διαθεσιμότητα: http://elib.usma.ru/handle/usma/4827
-
3Academic Journal
Συγγραφείς: L. P. Ananieva, S. N. Avdeev, I. Е. Tyurin, A. М. Lila, A. I. Zagrebneva, А. L. Maslyanskiy, S. A. Terpigorev, I. V. Stepanyan, E. L. Lashina, O. V. Vasilieva, O. S. Lukina, E S. Pershina, А. А. Klimenko, N. A. Shostak, E. L. Nasonov, Л. П. Ананьева, С. Н. Авдеев, И. Е. Тюрин, А. М. Лила, А. И. Загребнева, А. Л. Маслянский, С. А. Терпигорев, И. В. Степанян, Е. Л. Лашина, О. В. Васильева, О. С. Лукина, Е. С. Першина, А. А. Клименко, Н. А. Шостак, Е. Л. Насонов
Πηγή: Rheumatology Science and Practice; Vol 58, No 6 (2020); 631-636 ; Научно-практическая ревматология; Vol 58, No 6 (2020); 631-636 ; 1995-4492 ; 1995-4484
Θεματικοί όροι: нинтеданиб, immune-inflammatory rheumatic diseases, antifibrotic therapy, nintedanib, иммуновоспалительные ревматические заболевания, антифибротическая терапия
Περιγραφή αρχείου: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/2960/2034; Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med. 2020;383(10):958-968. DOI:10.1056/NEJMra2005230; Wong AW, Ryerson CJ, Guler SA. Progression of fibrosing interstitial lung disease. Respir Res. 2020;21(1):32. DOI:10.1186/s12931-020-1296-3; George PM, Spagnolo P, Kreuter M, et al.; Erice ILD working group. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med. 2020;8(9):925-934. DOI:10.1016/S2213-2600(20)30355-6; Vancheri C, Basile A. Multidisciplinary approach to interstitial lung diseases: Nothing is better than all of us together. Diagnostics (Basel). 2020;10(7):488. DOI:10.3390/diagnostics10070488; Furini F, Carnevale A, Casoni GL, et al. The role of the multidisciplinary evaluation of interstitial lung diseases: systematic literature review of the current evidence and future perspectives. Front Med (Lausanne). 2019;6:246. DOI:10.3389/fmed.2019.00246; Elicker BM, Kallianos KG, Henry TS. The role of high-resolution computed tomography in the follow-up of diffuse lung disease. Eur Resp Rev. 2017;26(144):170008. DOI:10.1183/16000617.0008-2017; Walsh SLF, Devaraj A, Enghelmayer JI, et al. Role of imaging in progressive-fibrosing interstitial lung diseases. Eur Resp Revc. 2018;27(150):180073. DOI:10.1183/16000617.0073-2018; Chanda D, Otoupalova E, Smith SR, et al. Developmental pathways in the pathogenesis of lung fibrosis. Mol Aspects Med. 2019;65:56-69. DOI:10.1016/j.mam.2018.08.004; Wijsenbeek M, Kreuter M, Olson A, et al. Progressive fibrosing interstitial lung diseases: Current practice in diagnosis and management. Curr Med Res Opin. 2019;35(11):2015-2024. DOI:10.1080/03007995.2019.1647040; Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: Incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014;2(7):566-572. DOI:10.1016/S2213-2600(14); Kolb M, Vas;ikov;i M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. 2019;20(1):57. DOI:10.1186/s12931-019-1022-1; Насонов ЕЛ, Александрова ЕН, Новиков АА. Аутоимунные ревматические заболевания - проблемы иммунопатологии и персонифицированной терапии. Вестник РАМН. 2015;(2):169-182. DOI:10.15690/vramn.v70i2.1310; Goldblatt F, O'Neill SG. Clinical aspects of autoimmune rheumatic diseases. Lancet. 2013;382(9894):797-808. DOI:10.1016/S0140-6736(13)61499-3; Atzeni F, Gerardi MC, Barilaro G, et al. Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review. Expert Rev Clin Immunol. 2018;14(1):69-82. DOI:10.1080/1744666X.2018.1411190; Fischer A, Distler J. Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. Clin Rheumatol. 2019;38(10):2673-2681. DOI:10.1007/s10067-019-04720-0; Sambataro D, Sambataro G, Pignataro F, et al. Patients with interstitial lung disease secondary to autoimmune diseases: How to recognize them? Diagnostics (Basel). 2020;10(4):208. DOI:10.3390/diagnostics10040208; Perelas A, Silver RM, Arrossi AV, et al. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020;8(3):304-320. DOI:10.1016/S2213-2600(19)30480-1; Barba T, Mainbourg S, Nasser M, et al. Lung diseases in inflammatory myopathies. Semin Respir Crit Care Med. 2019;40(2):255-270. DOI:10.1055/s-0039-1685187; Hervier B, Uzunhan Y. Inflammatory myopathy-related interstitial lung disease: From pathophysiology to treatment. Front Med (Lausanne). 2020;6:326. DOI:10.3389/fmed.2019.00326; Betteridge Z, Tansley S, Shaddick G, et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun. 2019;101:48-55. DOI:10.1016/j.jaut.2019.04.001; Long K, Danoff SK. Interstitial lung disease in polymyositis and dermatomyositis. Clin Chest Med. 2019;40(3):561-572. DOI:10.1016/j.ccm.2019.05.004; Gonzdlez-Moreno J, Raya-Cruz M, Losada-Lopez I, et al. Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: A case report and literature review. Rheumatol Int. 2018;38(7):1293-1296. DOI:10.1007/s00296-018-3991-7; Ciang NC, Pereira N, Isenberg DA. Mixed connective tissue disease - enigma variations? Rheumatology (Oxford). 2017;56(3):326-333. DOI:10.1093/rheumatology/kew265; Perelas A, Arrossi AV, Highland KB. Pulmonary manifestations of systemic sclerosis and mixed connective tissue disease. Clin Chest Med. 2019;40(3):501-518. DOI:10.1016/j.ccm.2019.05.001; Spagnolo P, Lee JS, Sverzellati N, et al. The lung in rheumatoid arthritis: Focus on interstitial lung disease. Arthritis Rheumatol. 2018;70(10):1544-1554. DOI:10.1002/art.40574; Bendstrup E, M0ller J, Kronborg-White S, et al. Interstitial lung disease in rheumatoid arthritis remains a challenge for clinicians. J Clin Med. 2019;8(12):2038. DOI:10.3390/jcm8122038; Wu EK, Ambrosini RD, Kottmann RM, et al. Reinterpreting evidence of rheumatoid arthritis-associated interstitial lung disease to understand etiology. Curr Rheumatol Rev. 2019;15(4):277-289. DOI:10.2174/1573397115666190116102451; George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: The potential role for antifibrotic therapy. Lancet Respir Med. 2020;8(8):807-815. DOI:10.1016/S2213-2600(20)30225-3; Spagnolo P, Balestro E, Aliberti S, et al. Pulmonary fibrosis secondary to COVID-19: A call to arms? Lancet Respir Med. 2020;8(8):750-752. DOI:10.1016/S2213-2600(20)30222-8; Mira-Avendano I, Abril A, Burger CD, et al. Interstitial lung disease and other pulmonary manifestations in connective tissue diseases. Mayo Clin Proc. 2019;94:309-325. DOI:10.1016/j.mayocp.2018.09.002; Акулкина ЛА, Бровко МЮ, Шоломова ВИ, и др. Интерстициальная пневмония с аутоиммунными признаками (ИПАП): мультидисциплинарный диагноз в пульмонологии и ревматологии. Клиническая фармакология и терапия. 2018;18(27):5-10.; Graney BA, Fischer A. Interstitial pneumonia with autoimmune features. Ann Am Thorac Soc. 2019;16(5):525-533. DOI:10.1513/AnnalsATS.201808-565CME; Wilfong EM, Lentz RJ, Guttentag A, et al. Interstitial pneumonia with autoimmune features: An emerging challenge at the intersection of rheumatology and pulmonology. Arthritis Rheumatol. 2018;70(12):1901-1913. DOI:10.1002/art.40679; Adegunsoye A, Oldham JM, Bellam SK, et al. Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases. Ann Am Thorac Soc. 2019;16(5):580-588. DOI:10.1513/AnnalsATS.201807-443OC; Wollin L, Distler JHW, Redente EF, et al. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J. 2019;54(3):1900161. DOI:10.1183/13993003.001612019; Landi C, Bergantini L, Cameli P, et al. Idiopathic pulmonary fibrosis serum proteomic analysis before and after nintedanib therapy. Sci Rep. 2020;10:9378. DOI:10.1038/s41598-020-66296-z; Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-2082. Erratum in: N Engl J Med. 2015;373(8):782. DOI:10.1056/NEJMoa1402584; Crestani B, Huggins JT, Kaye M, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: Results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2019;7(1):60-68. DOI:10.1016/S2213-2600(18)30339-4; Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518-2528. DOI:10.1056/NEJMoa1903076; Seibold JR, Maher TM, Highland KB, et al. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: Data from the SENSCIS trial. Ann Rheum Dis. 2020;79(11):1478-1484. DOI:10.1136/annrheumdis-2020-217331; Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718-1727. DOI:10.1056/NEJMoa1908681; Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8(5):453-460. DOI:10.1016/S2213-2600(20)30036-9; Авдеев СН, Ананьева ЛП, Жиляев ЕВ, и др. Резолюция Совета экспертов, посвященного теме «Интерстициальные заболевания легких при системной склеродермии» (14 октября 2019 г., Москва). Современная ревматология. 2020;14(1):125-128. DOI:10.14412/1996-7012-2020-1-125-128.; Sinha A, Patel AS, Siegert RJ, et al. The King's Brief Interstitial Lung Disease (KBILD) questionnaire: An updated minimal clinically important difference. BMJ Open Respir Res. 2019;6(1):e000363. DOI:10.1136/bmjresp-2018-000363; Liu R, Lei C, Liao X, et al. Semi-quantitative analysis for the dynamic chest CT imaging features from onset to recovery in severe and critical COVID-19. Radiol Infect Dis. 2020;7(3):114-122. DOI:10.1016/j.jrid.2020.07.003
-
4Academic Journal
Συγγραφείς: O. A. Chernyavskaya, A. V. Osipov, О. А. Чернявская, А. В. Осипов
Πηγή: Meditsinskiy sovet = Medical Council; № 12 (2021); 154-160 ; Медицинский Совет; № 12 (2021); 154-160 ; 2658-5790 ; 2079-701X
Θεματικοί όροι: бовгиалуронидаза азоксимер, COVID-19, pulmonary fibrosis, pathomorphogenesis, antifibrotic therapy, Bovhyaluronidazum azoximerum, пневмофиброз, патоморфогенез, антифибротическая терапия
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/6344/5743; Ojo A.S., Balogun S.A., Williams O.T., Ojo O.S. Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies. Pulm Med. 2020;2020:6175964. https://doi.org/10.1155/2020/6175964.; Schwensen H.F., Borreschmidt L.K., Storgaard M., Redsted S., Christensen S., Madsen L.B. Fatal Pulmonary Fibrosis: A Post-COVID-19 Autopsy Case. J Clin Pathol. 2020:jclinpath-2020-206879. https://doi.org/10.1136/jclinpath-2020-206879.; Fang Y., Zhou J., Ding X., Ling G., Yu S. Pulmonary Fibrosis in Critical Ill Patients Recovered from COVID-19 Pneumonia: Preliminary Experience. Am J Emerg Med. 2020;38(10):2134–2138. https://doi.org/10.1016/j.ajem.2020.05.120.; Faverio P., De Giacomi F., Bonaiti G., Stainer A., Sardella L., Pellegrino G. et al. Management of Chronic Respiratory Failure in Interstitial Lung Diseases: Overview and Clinical Insights. Int J Med Sci. 2019;16(7): 967–980. https://doi.org/10.7150/ijms.32752.; George P.M., Wells A.U., Jenkins R.G. Pulmonary Fibrosis and COVID-19: the Potential Role for Antifibrotic Therapy. Lancet Respir Med. 2020;8(8):807–815. https://doi.org/10.1016/S2213-2600(20)30225-3.; McDonald L.T. Healing after COVID-19: Are Survivors at Risk for Pulmonary Fibrosis? J Physiol Lung Cell Mol Physiol. 2021;320(2):L257–L265. https://doi.org/10.1152/ajplung.00238.2020.; Lu Z.H., Yang C.L., Yang G.G., Pan W.X., Tian L.G., Zheng J.X. et al. Efficacy of the Combination of Modern Medicine and Traditional Chinese Medicine in Pulmonary Fibrosis Arising as a Sequelae in Convalescent COVID-19 Patients: A Randomized Multicenter Trial. Infect Dis Poverty; 2021;10(1):31. https://doi.org/10.1186/s40249-021-00813-8.; Военнов О.В., Загреков В. И., Бояринов Г.А., Гераськин В.А., Бояринова Л.В. Механизмы развития легочного повреждения у пациентов с новой коронавирусной инфекцией (обзор литературы). Медицинский альманах. 2020;(3):15–26. Режим доступа: https://www.files.pimunn.ru/almanakh/2020/3-64%20сайт.pdf.; Vitiello A., Pelliccia C., Ferrara F. COVID-19 Patients with Pulmonary Fibrotic Tissue: Clinical Pharmacological Rational of Antifibrotic Therapy. SN Compr Clin Med. 2020:1–4. https://doi.org/10.1007/s42399-020-00487-7.; Wang J., Wang B.J., Yang J.C., Wang M.Y., Chen C., Luo G.X., He W.F. Research Advances in the Mechanism of Pulmonary Fibrosis Induced by Coronavirus Disease 2019 and the Corresponding Therapeutic Measures. Zhonghua Shao Shang Za Zhi. 2020;36(8):691–697. (In Chinese). https://doi.org/10.3760/cma.j.cn501120-20200307-00132.; Vasarmidi E., Tsitoura E., Spandidos D.A., Tzanakis N., Antoniou K.M. Pulmonary Fibrosis in the Aftermath of the COVID-19 Era (Review). Exp Ther Med. 2020;20(3):2557–2560. https://doi.org/10.3892/etm.2020.8980.; Болевич С.Б., Болевич C.C. Комплексный механизм развития СOVID-19. Сеченовский вестник. 2020;11(2):50–61. https://doi.org/10.47093/2218- 7332.2020.11.2.50-61.; Schön M.P., Berking C., Biedermann T., Buhl T., Erpenbeck L., Eyerich K. et al. COVID-19 and Immunological Regulations – from Basic and Translational Aspects to Clinical Implications. J Dtsch Dermatol Ges. 2020;18(8):795–807. https://doi.org/10.1111/ddg.14169.; Головкин А.С., Кудрявцев И.В., Дмитриев А.В., Калинина О.В. Фиброзные изменения сердечно-сосудистой и дыхательной систем после перенесенной COVID-19: вклад факторов иммунной системы и генетическая предрасположенность. Российский кардиологический журнал. 2020;25(10):4087. Режим доступа: https://russjcardiol.elpub.ru/jour/article/view/4087.; He X., Zhang L., Ran Q., Wang J., Xiong A., Wu D. et al. Integrative Bioinformatics Analysis Provides Insight into the Molecular Mechanisms of 2019-nCoV. medRxiv. 2020.02.03.20020206. https://doi.org/10.1101/2020.02.03.20020206.; Зайратьянц О.В., Малявин А.Г., Самсонова М.В., Черняев А.Л., Мишнев О.Д., Михалева Л.М. и др. Патоморфологические изменения в легких при COVID-19: клинические и терапевтические параллели. Терапия. 2020;(5):35–46. https://doi.org/10.18565/therapy.2020.5.35-46.; Забозлаев Ф.Г., Кравченко Э.В., Галлямова А.Р., Летуновский Н.Н. Патологическая анатомия легких при новой коронавирусной инфекции (CoVID-19). Предварительный анализ аутопсийных исследований. Клиническая практика. 2020;11(2):21–37. https://doi.org/10.17816/clinpract34849.; Yang J., Pan X., Wang L., Yu G. Alveolar Cells under Mechanical Stressed Niche: Critical Contributors to Pulmonary Fibrosis. Mol Med. 2020;26(1):95. https://doi.org/10.1186/s10020-020-00223-w.; Zhang P., Li J., Liu H., Han N., Ju J., Kou Y. et al. Long-Term Bone and Lung Consequences Associated with Hospitalacquired Severe Acute Respiratory Syndrome: A 15-Year Follow-Up from a Prospective Cohort Study. Bone Res. 2020;8(1). https://doi.org/10.1038/s41413-020-0084-5.; Spagnolo P., Balestro E., Aliberti S., Cocconcelli E., Biondini D., Casa G.D. et al. Pulmonary Fibrosis Secondary to COVID-19: A Call to Arms? Lancet Respir Med. 2020;8(8):750–752. https://doi.org/10.1016/S2213-2600(20)30222-8.; Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical Predictors of Mortality due to COVID-19 Based on an Analysis of Data of 150 Patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–848. https://doi.org/10.1007/s00134-020-05991-x.; Sun P., Qie S., Liu Z., Ren J., Li K., Xi J. Clinical Characteristics of Hospitalized Patients with SARS-CoV-2 Infection: A Single Arm Meta-Analysis. J Med Virol. 2020;92(6):612–617. https://doi.org/10.1002/jmv.25735.; Авдеев С.Н. Идиопатический легочный фиброз. Пульмонология. 2015;25(5): 600–612. https://doi.org/10.18093/0869-0189-2015-25-5-600-612.; Дворецкий Л.И. Интерстициальные заболевания легких у пожилых. Пульмонология. 2014;(4):91–99. https://doi.org/10.18093/0869-0189-2014-0-4-91-99.; Udwadia Z.F., Koul P.A., Richeldi L. Post-COVID Lung Fibrosis: The tsunami that Will Follow the Earthquake. Lung India. 2021;38(Suppl.):S41–S47. https://doi.org/10.4103/lungindia.lungindia_818_20.; Peter M.G., Athol U.W., Jenkins R.G. Pulmonary Fibrosis and COVID-19: the Potential Role for Antifibrotic Therapy. Lancet Respir Med. 2020;8(8):807–815. https://doi.org/10.1016/S2213-2600(20)30225-3.; Leo F., Wormanns D., Grohé C. COVID-19: A Pneumological Point of View – Long-Term Sequelae of COVID-19 – Implications for Follow-Up in Respiratory Medicine. Dtsch Med Wochenschr. 2020;145(15):1086–1092. (In German) https://doi.org/10.1055/a-1164-4040.; Yu M., Liu Y., Xu D., Zhang R., Lan L., Xu H. Prediction of the Development of Pulmonary Fibrosis Using Serial Thin-Section CT and Clinical Features in Patients Discharged after Treatment for COVID-19 Pneumonia. Korean J Radiol. 2020;21(6):746–755. https://doi.org/10.3348/kjr.2020.0215.; Чучалин А.Г., Авдеев С.Н., Айсанов З.Р., Белевский А.С., Демура С.А., Илькович М.М. и др. Диагностика и лечение идиопатического легочного фиброза. Федеральные клинические рекомендации. Пульмонология. 2016;26(4):399–421. https://doi.org/10.18093/0869-0189-2016-26-4-399-419.; Gentile F., Aimo A., Forfori F., Catapano G., Clemente A., Cademartiri F. et al. COVID-19 and Risk of Pulmonary Fibrosis: the Importance of Planning Ahead. Eur J Prev Cardiol. 2020;27(13):1442–1446. https://doi.org/10.1177/2047487320932695.; Бутов Ю.С., Васенова В.Ю. Возможности применения и терапевтическая эффективность лонгидазы при патологиях соединительной ткани. Эффективная фармакотерапия. Дерматовенерология и дерматокосметология. 2012;11(2):40–43. Режим доступа: https://umedp.ru/articles/vozmozhnosti_primeneniya_i_terapevticheskaya_effektivnost_longidazy_pri_patologiyakh_soedinitelnoy_t.html.; Зайцев А.В., Ходырева Л.А., Дударева А.А., Пушкарь Д.Ю. Современный взгляд на применение ферментных препаратов у больных хроническим простатитом. Клиническая дерматология и венерология. 2016;15(3): 53–60. https://doi.org/10.17116/klinderma201615353-60.; Смирнова Л.Е., Умаханова М.М., Торчинов А.М. Современные взгляды на спаечный процесс в брюшной полости при трубно-перитонеальном бесплодии. Акушерство и гинекология. 2016;(11):148–152. https://doi.org/10.18565/aig.2016.11.148-52.; Самцов А.В., Лучина Е.Н. Клинический опыт применения препаратов на основе гиалуронидазы: комплексная терапия рубцовых деформаций кожи. Экспериментальная и клиническая дерматокосметология. 2012;(6):28–32. Режим доступа: https://ekd.rusvrach.ru/ru/derm-2012-06-06.; Кирюхина Т.А., Авдошин В.П., Андрюхин М.И., Пульбере С.А. Эффективность лонгидазы в профилактике рубцово-склеротических процессов после оперативных вмешательств на мочевых путях. Вестник Российского университета дружбы народов. Серия: Медицина. 2013;(1):84–88. Режим доступа: http://journals.rudn.ru/medicine/article/view/3210.; Доброхотова Ю.Э., Филатова Л.А., Гришин И.И. Результаты применения бовгиалуронидазы азоксимера в комплексной терапии воспалительных заболеваний органов малого таза. РМЖ. 2018;26(2–1):19–22. Режим доступа: https://www.rmj.ru/articles/ginekologiya/Rezulytaty_primeneniya_bovgialuronidazy_azoksimera_vkompleksnoy_terapii_vospalitelynyh_zabolevaniy_organov_malogo_taza/; Стенько А.Г., Талыбова А.М., Круглова Л.С., Корчажкина Н.Б. Применение конъюгированной гиалуронидазы для профилактики и лечения рубцовых деформаций. Кремлевская медицина. Клинический вестник. 2018;(1):114–119. Режим доступа: https://kremlin-medicine.ru/index.php/km/article/view/1057.; Балан В.Е., Журавель А.С. Возможности применения препаратов, содержащих гиалуроновую кислоту, в гинекологии. Эффективная фармакотерапия. 2014;(23):50–54. Режим доступа: https://umedp.ru/upload/iblock/b99/b990f1fb1bbd928c2207d1d67025211f.pdf.; Новикова Л.Н., Захарова А.С., Дзадзуа Д.В., Баранова О.П., Корзина Н.В., Сперанская А.А. и др. Результаты применения Лонгидазы у больных идиопатическим фиброзирующим альвеолитом. Доктор.Ру. 2011;(6): 50–54. Режим доступа: https://elibrary.ru/item.asp?id=17764510.; Костинов М.П. (ред.). Основы иммунореабилитации при новой коронавирусной инфекции (COVID-19). М.: Группа МДВ; 2020. 112 с. Режим доступа: https://vakcina.ru/files/tmpfiles/upload-documents/COVID-19/osnovy-immunoreabilitacii-covid19--kostinov.pdf.
-
5Academic Journal
Συγγραφείς: N. A. Kuzubova, O. N. Titova, D. B. Skliarova, Н. А. Kузубовa, О. Н. Tитовa, Д. Б. Склярова
Πηγή: Meditsinskiy sovet = Medical Council; № 17 (2020); 99-106 ; Медицинский Совет; № 17 (2020); 99-106 ; 2658-5790 ; 2079-701X
Θεματικοί όροι: антифибротическая терапия, interstitial lung diseases, fibrosis, myofibroblasts, antifibrotic therapy, интерстициальные заболевания легких, фиброз, миофибробласты
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/5882/5367; Brown K.K., Martinez F.J., Walsh S.L.F., Thannickal V.J., Antje P., SchlenkerHerceg R. et al. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020;55(6):2000085. doi:10.1183/13993003.00085-2020.; Cottin V., Wollin L., Fischer A., Quaresma M., Stowasser S., Harari S. Fibrosing interstitial lung disease: knowns and unknowns. Eur Respir Rev. 2019;28(151):180100. doi:10.1183/16000617.0100-2018.; Wong A.W., Ryerson C.J., Guler S.A. Progression of fibrosing interstitial lung disease. Respir Res. 2020;21(1):32. doi:10.1186/s12931-020-1296-3.; Harari S. Beyond idiopathic pulmonary fibrosis: the world of progressivefibrosing interstitial lung disease. Eur Respir Rev. 2018;27(150):180110. doi:10.1183/16000617.0110-2018.; Cottin V., Hirani N.A., Hotchkin D.L., Nambiar A.M., Ogura T., Otaola M. et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180076. doi:10.1183/16000617.0076-2018.; Olson A.M., Gifford A.H., Inase N., Fernández Pérez E.R., Suda T. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype. Eur Respir Rev. 2018;27(150):180077. doi:10.1183/16000617.0077-2018.; Kolb M., Vašáková M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. 2019;20(1):57. doi:10.1186/s12931-019-1022-1.; Elhai M., Meune C., Boubaya M., Avouac J., Hachulla E., Balbir-Gurnan A. et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76(11):1897–1905. doi:10.1136/annrheumdis-2017-211448.; Solomon J.J., Chung J.H., Cosgrove G.P., Dernoruelle M.K., Fernandez-Perez E.R., Fischer A. et al. Predictors of mortality in rheumatoid arthritis-associated lung disease. Eur Respir J. 2016;47(2):588–596. doi:10.1183/13993003.00357-2015.; Fernandez-Perez E.R., Kong A.M., Raimundo K., Koelsch T.L., Kulkarni R., Cole A.L. Epidemiology of hypersensitivity pneumonitis among an insured population in the United States: a claim-based cohort analysis. Ann Am Thorac Soc. 2018;15(4):460–469. doi:10.1513/AnnalsATS.201704-288OC.; Park I.N., Jegal Y., Kim D.S., Do K.H., Yoo B., Shim T.S. et al. Clinical course and lung function change of idiopathic nonspecific interstitial pneumonia. Eur Respir J. 2009;33(1):68–76. doi:10.1183/09031936.00158507.; Wynn T.A., Ramalingam T.R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18(7):1028–1040. doi:10.1038/nm.2807.; Huang E., Peng N., Xiao F., Hu D., Wang X., Lu L. The roles of immune cells in the pathogenesis of fibrosis. Int J Mol Sci. 2020;21(15):5203. doi:10.3390/ijms21155203.; Шурыгина И.А., Шурыгин М.Г., Аюшинова Н.И., Каня О.В. Фибробласты и их роль в развитии соединительной ткани. Сибирский медицинский журнал. 2012;(3):8–12. Режим доступа: https://elibrary.ru/item.asp?id=17761929.; Hironaka T., Ueno T., Mae K., Yoshimura C., MorinagaT., Horii Y. et al. Drebrin is induced during myofibroblast differentiation and enhances the production of fibrosis-related genes. Biochem Biophys Res Commun. 2020;529(2):224–230. doi:10.1016/j.bbrc.2020.05.110.; Hinz B. Formation and function of the myofibroblast during tissue repair. J Invest Dermatol. 2007;127(3):526–537. doi:10.1038/sj.jid.5700613.; Hu B., Wu Z., Phan S.H. Smad3 mediates transforming growth factor-betainduced alpha-smooth muscle actin expression. Am J Respir Cell Mol Biol. 29(3 Pt 1):397–404. doi:10.1165/rcmb.2003-0063OC.; Mukherjee S., Kolb M.R.J., Duan F., Janssen L.J. Transforming growth factorß evokes Ca2+ wavwes and enhances gene expression in human pulmonary fibroblasts. Am J Cell Mol Biol. 2012;46(6):757–764. doi:10.1165/rcmb.2011-0223OC.; Merkt W., Bueno M., Mora A.L., Lagares D. Senotherapeutics: Targeting senescence in idiopathic pulmonary fibrosis. Semin Cell Dev Biol. 2020;101:104–110. doi:10.1016/j.semcdb.2019.12.008.; Ley B., Liu S., Elicker B.M., Henry T.S., Vittinghoff E., Golden1 J.A. et al. Telomere length in patients with unclassifiable interstitial lung disease: a cohort study. Eur Respir J. 2020;56(2):2000268. doi:10.1183/13993003.00268-2020.; Maity S., Muhamed J., Sarikhani M., Kumar S., Ahamed F., Spurthi K.M. et al. Sirtuin 6 deficiency transcriptionally up-regulates TGF-β signaling and induces fibrosis in mice. J Biol Chem. 2020;295(2):415–434. doi:10.1074/jbc.RA118.007212.; Juge P.A., Lee J.S., Ebstein E., Furukawa H., Dobrinskikh E., Gazal S. et al. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med. 2018;379(23):2209–2219. doi:10.1056/NEJMoa1801562.; Ley B., Newton C.A., Arnould I., Elicker B.M., Henry T.S., Vittinghoff E. et al. The MUC5B promoter polymorphism and thelomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study. Lancet Respir Med. 2017;5(8):639–647. doi:10.1016/S2213-2600(17)30216-3.; Otoupalova E., Smith S., Cheng G., Thannickal V.J. Oxidative Stress in Pulmonary Fibrosis. Compr Physiol. 2020;10(2):509–547. doi:10.1002/cphy.c190017.; Richeldi L., Varone F., Bergna M., de Andrade J., Falk J., Hallowell R. et al. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. Eur Respir Rev. 2018;27(150):180074. doi:10.1183/16000617.0074-2018.; Cassone G., Sebastiani M., Vacchi C., Cerri S., Salvarani C., Manfredi A. Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming? Respir Med Case Rep. 2020;30:101051. doi:10.1016/j.rmcr.2020.101051.; Collins B.F., Raghu G. Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis. Eur Respir Rev. 2019;28(153):190022. doi:10.1183/16000617.0022-2019.; Wollin L., Distler J.H.W., Redente E.F., Riches D.W.H., Stowasser S., Schlenker-Herceg R. et al. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J. 2019;54(3):1900161. doi:10.1183/13993003.00161-2019.; Torrisi S.E., Kahn N., Wälscher J., Sarmand N., Polke M., Lars K. et al.Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases. BMC Pulm Med. 2019;19(1):213. doi:10.1186/s12890-019-0937-0.; Gulati S., Luckhardt T.L. Updated Evaluation of the Safety, Efficacy and Tolerability of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis. Drug Healthc Patient Saf. 2020;12:85–94. doi:10.2147/DHPS.S224007.; Noble P.W., Albera C., Bradford W.Z., Costabel U., Glassberg M.K., Kardatzke D. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet Lond Engl. 2011;377(9779):1760–1769. doi:10.1016/S0140-6736(11)60405-4.; King T.E., Bradford W.Z., Castro-Bernardini S., Fagan E.A., Сlaspole I., Glassberg M.K. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092. doi:10.1056/NEJMoa1402582.; Cassone G., Manfredi A., Vacchi C., Luppi F., Coppi F., Salvarani C., Sebastiani M. Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows. J Clin Med. 2020;9(4):1082. doi:10.3390/jcm9041082.; Wind S., Schmid U., Freiwald M., Marzin K., Lotz R., Ebner T. et al. Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib. Clin Pharmacokinet. 2019;58(9):1131–1147. doi:10.1007/s40262-019-00766-0.; Wollin L., Ostermann A., Williams C. Nintedanib inhibits pro-fibrotic mediators from T cells with relevance to connective tissue disease-associated interstitial lung disease. Eur Respir J. 2017;50(61):PA903. doi:10.1183/1393003.congress-2017.PA903.; Mazzei M., Richeldi L., Collard H.R. Nintedanib in the treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis. 2015;9(3):121–129. doi:10.1177/1753465815579365.; Richeldi L., Cottin V., du Bois R.M., Selman M., Kimura T., Bailes Z. et al. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials. Respir Med. 2016;113:74–79. doi:10.1016/j.rmed.2016.02.001.; Vasakova M., Sterclova M., Mogulkoc N., Lawandowska K., Müller V., Hajkova M. et al. Long-term overall survival and progression-free survival in idiopathic pulmonary fibrosis treated by pirfenidone or nintedanib or their switch. Real world data from the EMPIRE registry. Eur Respir J. 2019;54(Suppl. 63):PA4720. doi:10.1183/13993003.congress-2019.PA4720.; Бровко М.Ю., Акулкина Л.А., Шоломова В.И., Новиков П.И., Янакаева А.Ш., Моисеев С.В. Новые подходы к лечению фиброзирующих интерстициальных заболеваний легких. Клиническая фармакология и терапия. 2020;29(1):61–66. doi:10.32756/0869-5490-2020-1-61-66.; Wells A.U., Flaherty K.R., Brown K.K., Inoue Y., Devaraj A., Richeldi L. et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallelgroup trial. Lancet Respir Med. 2020;8(5):453–460. doi:10.1016/S2213-2600(20)30036-9.
-
6Academic Journal
Συγγραφείς: L. Alekseeva I., S. Terpigorev A., E. Zonova V., L. Kudelya M., N. Babadaeva M., A. Teteneva V., A. Kondrashov A., D. Orlov N., T. Raskina V., O. Anoshenkova N., Yu. Chasovskikh P., T. Kropotina V., A. Opongosheva B., N. Yudina V., N. Ganyukova G., Л. Алексеева И., С. Терпигорев А., Е. Зонова В., Л. Куделя М., Н. Бабадаева М., А. Тетенева В., А. Кондрашов А., Д. Орлов Н., Т. Раскина В., О. Аношенкова Н., Ю. Часовских П., Т. Кропотина В., А. Опонгошева Б., Н. Юдина В., Н. Ганюкова Г.
Πηγή: Bulletin of Siberian Medicine; Том 19, № 3 (2020); 113-119 ; Бюллетень сибирской медицины; Том 19, № 3 (2020); 113-119 ; 1819-3684 ; 1682-0363 ; 10.20538/1682-0363-2020-19-3
Θεματικοί όροι: systemic sclerosis, interstitial lung diseases, nintedanib, anti-fibrotic therapy, системная склеродермия, интерстициальные заболевания легких, нинтеданиб, антифибротическая терапия
Περιγραφή αρχείου: application/pdf
Relation: https://bulletin.tomsk.ru/jour/article/view/2994/1799; https://bulletin.tomsk.ru/jour/article/view/2994/2240; Интерстициальные и орфанные заболевания легких; под ред. М.М. Ильковича. М.: ГЭОТАР-Медиа, 2019: 384–390.; Frantz C., Avouac J., Distler O. et al. Impaired quality of life in systemic sclerosis and patient perception of the disease: a large international survey. Semin. Arthritis Rheum. 2016; 46 (1): 115–123. DOI:10.1016/j.semarthrit.2016.02.005.; Fischer A., Zimovetz E., Ling C., Esser D., Schoof N. Humanistic and cost burden of systemic sclerosis: a review of the literature. Autoimmun. Rev. 2017; 16 (11): 1147–1154. DOI:10.1016/j.autrev.2017.09.010.; Tashkin D.P., Elashoff R., Clements P.J. et al. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. 2006; 354: 2655–2066. DOI:10.1056/NEJMoa055120.; Tashkin D.P., Roth M.D., Clements P.J. et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomized controlled, double-blind, parallel group trial. Lancet Respir. Med. 2016; 4 (9): 708–719. DOI:10.1016/S2213-2600(16)30152-7.; Richeldi L., du Bois R.M., Raghu G. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370 (22): 2071–2082. DOI:10.1056/NEJMoa1402584.; Wollin L., Wex E., Pautsch A. et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur. Respir. J. 2015; 45 (5): 1434–1445. DOI:10.1183/09031936.00174914.; Richeldi L., Costabel U., Selman M. et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2011; 365 (12): 1079–1087. DOI:10.1056/NEJMoa1103690.; Distler O. et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N. Engl. Med. 2019; 380: 2518–2528. DOI:10.1056/NEJMoa1903076.; https://bulletin.tomsk.ru/jour/article/view/2994
-
7Academic Journal
Συγγραφείς: L. I. Alekseeva, S. A. Terpigorev, E. V. Zonova, L. M. Kudelya, N. M. Babadaeva, A. V. Teteneva, A. A. Kondrashov, D. N. Orlov, T. V. Raskina, O. N. Anoshenkova, Yu. P. Chasovskikh, T. V. Kropotina, A. B. Opongosheva, N. V. Yudina, N. G. Ganyukova
Πηγή: Бюллетень сибирской медицины, Vol 19, Iss 3, Pp 113-119 (2020)
Θεματικοί όροι: системная склеродермия, интерстициальные заболевания легких, нинтеданиб, антифибротическая терапия, Medicine
Relation: https://bulletin.ssmu.ru/jour/article/view/2994; https://doaj.org/toc/1682-0363; https://doaj.org/toc/1819-3684; https://doaj.org/article/ed3f55c0201841c4a4916cb184a1c1c4
-
8Academic Journal
Συγγραφείς: S. N. Avdeev, N. V. Trushenko, С. Н. Авдеев, Н. В. Трушенко
Πηγή: Meditsinskiy sovet = Medical Council; № 15 (2018); 131-136 ; Медицинский Совет; № 15 (2018); 131-136 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2018-15
Θεματικοί όροι: пирфенидон, treatment, antifibrotic therapy, pirfenidone, лечение, антифибротическая терапия
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/2682/2644; Авдеев С.Н. Идиопатический легочный фиброз. Пульмонология, 2015, 25 (5): 600-612.; Авдеев С.Н. Идиопатический фиброз легких: новая парадигма. Тер архив, 2017, 89(1): 112122.; Чучалин А.Г., Авдеев С.Н., Айсанов З.Р., Белевский А.С., Демура С.А., Илькович М.М., Коган Е.А. и др. Диагностика и лечение идиопатического легочного фиброза. Федеральные клинические рекомендации. Пульмонология, 2016, 26(4): 399-419.; Raghu G, Collard H, Egan JJ, Martinez FJ, Behr J, Brown KK An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am J Respir Crit Care Med, 2011, 183: 788–824. doi:10.1164/rccm.2009-040GL.; Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ, Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fbrosis. N Engl J Med, 2012, 366(21): 1968–1977.; Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med, 2011, 365: 1079– 1087.; Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, et al, INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med, 2014, 370: 2071–2082.; Lyer SN, Hyde DM, Giri SN. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation, 2000, 24(5): 477-91.; Fernandez IE, Eickelberg O. The impact of TGF-β on lung fibrosis: from targeting to biomarkers. Proc Am Thorac Soc, 2012, 9(3): 111-6.; Card JW, Racz WJ, Brien JF, Margolin SB, Massey TE. Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity. Toxicol Sci, 2003; 75(1): 169-80.; Togami K, Kanehira Y, Tada H. Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for idiopathic pulmonary fibrosis. Biol Pharm Bull, 2013, 36(10): 1525-7.; Kakugawa T, Mukae H, Hayashi T, et al. Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur Respir J, 2004, 24(1): 57-65.; Shi S, Wu J, Chen H, Zeng F. Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol, 2007, 47(10): 1268-76.; King CS, Nathan SD. Practical considerations in the pharmacologic treatment of idiopathic pulmonary fbrosis. Curr Opin Pulm Med, 2015, 21(5): 479–489.; Meyer KC, Decker CA. Role of pirfenidone in the management of pulmonary fibrosis. Therapeutics and Clinical Risk Management, 2017, 13: 427-437.; Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPATY): two randomised trials. Lancet, 2011, 377(9779): 1760-9.; King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med, 2014, 370(22): 2083-92.; George PM, Wells AU. Pirfenidone for the treatment of Idiopathic Pulmonary Fibrosis. Expert Review of Clinical Pharmacology, 2017. doi:10.1080/17512433.2017.1295846.; Costabel U, Albera C, Bradford WZ, Hormel P et al. Analysis of lung function and survival in RECAP: an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis, 2014, 31(3): 198–205.; Визель А.А, Белевский А.С. Современные аспекты лечения идиопатического легочного фиброза. Практическая пульмонология, 2017, 2: 93-98. /Wiesel AA, Belevsky AS. Modern aspects of the treatment of idiopathic pulmonary fibrosis. Prakticheskaya Pulmonologiya, 2017, 2: 93-98.; Ley B, Swigris J, Day BM, Stauffer JL, Raimundo K, Chou W, et al. Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2017, 196: 756–61. doi:10.1164/rccm.2017010091OC.; Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fbrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J, 2016, 47(1): 243–253.; Bargagli E, Piccioli C, Rosi E, Torricelli E, Turi L, Piccioli E et al. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre. Pulmonology, 2018 Sep 17. pii:S2531-0437(18)30099-0.; Yan YJ, Fan YL, Yu SW, Ye Q Real-life experience with pirfenidone in idiopathic pulmonary fibrosis. Zhonghua Jie He He Hu Xi Za Zhi, 2018 May 12, 41(5): 327-332.; Ogawa K, Miyamoto A, Hanada S, Takahashi Y, Murase K, Mochizuki S The efficiacy and safety of long-term pirfenidone therapy in patients with idiopathic pulmonary fibrosis. Intern Med, 2018 May 18. doi:10.2169/internalmedicine.0559-17.; Tzouvelekis A, Ntolios P, Karampitsakos T, Tzilas V, Anevlavis S, Bouros E, et al. Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis: a real-world observational study. Pulm Pharmacol The, 2017, 46: 48–53. doi:10.1016/j.pupt.2017.08.011.; Vancheri C, Kreuter M, Richeldi L, Ryerson CJ, Valeyre D, Grutters JC, Wiebe S, Stansen W, Quaresma M, Stowasser S, et al. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. Am J Respir Crit Care Med, 2018, 197: 356– 363. doi:10.1164/rccm.201706-1301OC.; Ogura T, Taniguchi H, Azuma A, Inoue Y, Kondoh Y, Hasegawa Y, Bando M, Abe S, Mochizuki Y, Chida K, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J, 2015, 45: 1382–1392. doi:10.1183/09031936.00198013.; Behr J, Bendstrup E, Crestani B, et al. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebocontrolled, phase 2 trial. Lancet Respir Med, 2016, 4(6): 445–453.; Azuma A, Nukiwa T, Tsuboi E, et al. Doubleblind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2005, 171(9): 1040-7.; Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J, 2010, 35(4): 821-9.; Glassberg M, Nathan SD, Lin CY, Lew C, Raimun do K, Stauffer J, Chou W, Noble PW. Cardiovascular Events in Phase 3 Trials of Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF). Am J Respir Crit Care Med, 2016, 193: A4980.; Valeyre D, Albera C, Bradford WZ, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology, 2014, 19(5): 740-7.